Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:endDate |
2021
|
| gptkbp:location |
gptkb:Latin_America
gptkb:South_Africa gptkb:United_States |
| gptkbp:participants |
~44,000
|
| gptkbp:period |
Phase 3
|
| gptkbp:principalInvestigator |
gptkb:Mathai_Mammen
|
| gptkbp:purpose |
evaluate efficacy and safety of Ad26.COV2.S vaccine
|
| gptkbp:result |
66% efficacy against moderate to severe COVID-19
prevention of moderate to severe COVID-19 |
| gptkbp:resultPublication |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:sponsor |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:startDate |
2020
|
| gptkbp:studiedBy |
gptkb:Ad26.COV2.S_vaccine
|
| gptkbp:trialIdentifier |
gptkb:NCT04505722
|
| gptkbp:vaccineRegimen |
single dose
|
| gptkbp:bfsParent |
gptkb:Janssen_COVID-19_vaccine
gptkb:Janssen_COVID-19_Vaccine |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
ENSEMBLE trial
|